Pravastatin--ocular side effects after a two year follow-up?

Lens Eye Toxic Res. 1990;7(3-4):311-8.

Abstract

Pravastatin, a new HMG-CoA-reductase inhibitor, was administered to hypercholesterolemic 14 patients with coronary heart disease for a period of two years. This drug reduces the plasma LDL-cholesterol concentrations approximately 30-40%. No development of cataracts or other ocular side effects could be observed during this two year follow-up.

MeSH terms

  • Aged
  • Anticholesteremic Agents / adverse effects*
  • Anticholesteremic Agents / therapeutic use
  • Cataract / chemically induced*
  • Cholesterol, LDL / blood
  • Female
  • Follow-Up Studies
  • Heptanoic Acids / adverse effects*
  • Heptanoic Acids / therapeutic use
  • Humans
  • Hypercholesterolemia / drug therapy
  • Lens, Crystalline / drug effects*
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Naphthalenes / adverse effects*
  • Naphthalenes / therapeutic use
  • Pravastatin
  • Triglycerides / blood

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Heptanoic Acids
  • Naphthalenes
  • Triglycerides
  • Pravastatin